NASDAQ: $SABS New Hope for Type 1 Diabetes Treatment The landscape of diabetes management is shifting as SAB Biotherapeutics recently announced a significant milestone for their investigative therapy, SAB-142. The FDA has officially granted Fast Track designation to this novel treatment, aimed at patients currently in Stage 3 Type 1 diabetes. What is SAB-142? SAB-142…